UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                ----------------


                                    FORM 8-A

                FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
                    PURSUANT TO SECTION 12(b) OR 12(g) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                         Bio-Imaging Technologies, Inc.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)


              Delaware                                   11-2872047
----------------------------------------       ---------------------------------
(State of Incorporation or Organization)       (IRS Employer Identification No.)


      826 Newtown-Yardley Road
        Newtown, Pennsylvania                              18940
----------------------------------------       ---------------------------------
(Address of Principal Executive Offices)                (Zip Code)


If this form relates to the  registration  of a class of securities  pursuant to
Section  12(b)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(c), please check the following box. |_|


If this form relates to the  registration  of a class of securities  pursuant to
Section  12(g)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(d), please check the following box. |X|


SECURITIES ACT REGISTRATION STATEMENT FILE NUMBER TO WHICH THIS FORM RELATES:
      N/A
-----------------
(If applicable)

SECURITIES TO BE REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:

   Title of Each Class                        Name of Each Exchange on Which
   to be so Registered                        Each Class is to be Registered
   -------------------                        ------------------------------

None.


SECURITIES TO BE REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:

                        Common Stock, $0.00025 par value
                        --------------------------------
                                (Title of Class)




                 INFORMATION REQUIRED IN REGISTRATION STATEMENT


ITEM 1.     DESCRIPTION OF REGISTRANT'S SECURITIES TO BE REGISTERED.

     The capital stock of Bio-Imaging Technologies, Inc., a Delaware corporation
(the "Company"), to be registered on the Nasdaq National Market is the Company's
common stock, $0.00025 par value per share (the "Common Stock").

     Each share of Common Stock  entitles the holder  thereof to one vote on all
matters submitted to a vote of the stockholders.  The holders of Common Stock do
not have  preemptive  rights,  sinking  fund  rights or rights to convert  their
Common Stock into other securities. The Company has no right to redeem shares of
its Common Stock.  Holders of Common Stock are entitled to receive  ratably such
dividends  as may be  declared by the Board of  Directors  of the Company out of
legally  available funds. In the event of a liquidation,  dissolution or winding
up,  holders  of the  Common  Stock  have the right to a ratable  portion of the
assets remaining after payment of liabilities, subject to any superior claims of
any shares of the then outstanding preferred stock, $0.00025 par value per share
(the  "Preferred  Stock").  The rights of the holders of the Common Stock may be
subject to the rights of the Preferred  Stock that may be issued by the Board of
Directors without stockholder approval.

     PROVISIONS  OF THE  CERTIFICATE  OF  INCORPORATION  AND THE  BYLAWS  OF THE
COMPANY THAT MAY PREVENT A CHANGE IN CONTROL

     The Company's  Certificate of  Incorporation,  as amended and restated from
time to time,  authorizes  1,750,000  shares of  Preferred  Stock.  The Board of
Directors has authority,  without further vote of the  stockholders,  to provide
for the  issuance  of all or any  shares of the  Preferred  Stock in one or more
classes  or  series,  and to fix for each  such  class  or  series  the  rights,
preferences, privileges and restrictions thereof, including, without limitation,
dividend rights,  dividend rates,  conversion rights into other capital stock of
the  Company,  voting  rights,  terms of  redemption,  redemption  prices or the
designations of such series.

     The issuance of Preferred Stock may have the effect of delaying, deferring,
or preventing a change in control of the Company  without  further action by the
stockholders and may adversely affect the voting and other rights of the holders
of Common  Stock.  At  present,  the  Company has not issued and has no plans to
issue any of the Preferred Stock.




     The Company's  Bylaws, as amended and restated from time to time, allow the
Board of Directors  to increase the number of directors  serving on the Board of
Directors,  and the  Bylaws  state  that a vacancy  on the  Board of  Directors,
whether caused by resignation, death, disqualification,  removal, an increase in
the  authorized  number  of  directors  or  otherwise,  may  be  filled  by  the
affirmative vote of a majority of the remaining directors,  although less than a
quorum,  or by a  sole  remaining  director,  or at a  special  meeting  of  the
stockholders  called by the  President,  or a vote of a majority of the Board of
Directors.  This  provision  of the  Bylaws  may have the  effect  of  delaying,
deferring,  or  preventing  a change in control of the Company,  may  discourage
potential acquisition  proposals,  and may have the effect of preventing changes
in the management of the Company.

ITEM 2.       EXHIBITS.

              Not applicable.






                                    SIGNATURE

     Pursuant to the  requirements of Section 12 of the Securities  Exchange Act
of 1934, the registrant has duly caused this registration statement to be signed
on its behalf by the undersigned, thereto duly authorized.

                                              Bio-Imaging Technologies, Inc.


Date: December 16, 2003                       By: /s/ Ted I. Kaminer
                                                 -------------------------------
                                                 Ted I. Kaminer
                                                 Chief Financial Officer